Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ABM Therapeutics Begins China Phase I Trial of BRAF Inhibitor for Brain Tumors

publication date: Sep 5, 2023

ABM Therapeutics, a Shanghai-San Diego biopharma, dosed the first patient in a multicenter China Phase I study of its lead drug in patients with relapsed and drug resistant malignant brain tumors. ABM-1310 is a brain-penetrating small molecule next-gen BRAF inhibitor. In pre-clinical tests, the candidate showed promise for treating cancer metastases in the brain. ABM has two clinical trials of AMB-1310 already under way for BRAF V600X mutated solid tumors: a China trial for melanoma with brain mets and a US study for colorectal cancer. ABM develops small molecule drugs for brain cancers and brain metastases. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital